Skye Bioscience Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Skye Bioscience şirketinin kazançları yıllık ortalama -50.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında arttı.

Anahtar bilgiler

-50.8%

Kazanç büyüme oranı

-10.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-28.0%
Net Marj	n/a
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11

Gelir ve Gider Dağılımı

Skye Bioscience nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:SKYE Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	-21	11	13
30 Jun 24	-42	13	9
31 Mar 24	-37	10	7
31 Dec 23	-38	8	6
30 Sep 23	-43	13	6
30 Jun 23	-21	12	6
31 Mar 23	-22	13	6
31 Dec 22	-19	12	6
30 Sep 22	-12	6	6
30 Jun 22	-11	6	4
31 Mar 22	-9	5	4
31 Dec 21	-9	5	3
30 Sep 21	-8	5	2
30 Jun 21	-7	4	2
31 Mar 21	-6	4	2
31 Dec 20	-7	4	2
30 Sep 20	0	5	2
30 Jun 20	-4	4	2
31 Mar 20	13	5	3
31 Dec 19	1	4	2
30 Sep 19	-10	4	2
30 Jun 19	-7	4	1
31 Mar 19	-26	4	1
31 Dec 18	-19	4	0
30 Sep 18	-14	4	0
30 Jun 18	-12	4	0
31 Mar 18	-10	4	0
31 Dec 17	-4	4	0
30 Sep 17	-5	4	0
30 Jun 17	-5	4	0
31 Mar 17	-4	4	1
31 Dec 16	-4	4	1
30 Sep 16	-3	4	1
30 Jun 16	-3	4	1
31 Mar 16	-6	4	0
31 Dec 15	-5	4	0
30 Sep 15	-6	5	0
30 Jun 15	-6	5	0
31 Mar 15	-4	3	0
31 Dec 14	-3	3	0
30 Sep 14	-1	1	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0

Kaliteli Kazançlar: SKYE şu anda kârlı değil.

Büyüyen Kar Marjı: SKYE şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SKYE kârlı değildir ve zararlar son 5 yılda yılda 50.8% oranında artmıştır.

Büyüme Hızlandırma: SKYE 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SKYE kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SKYE hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -28.02% ) sahiptir.

Skye Bioscience Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Recent updates

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor

Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model

Skye Bioscience, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Skye Bioscience Names Paul Grayson as Chairman of the Board

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer

Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab

Skye Bioscience, Inc. Appoints Dr. Karen Smith to Board of Directors, Effective August 1, 2024

Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program

Skye Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

High number of new directors

Skye Bioscience, Inc. announced that it has received $40 million in funding from 5AM Venture Management, LLC

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

Skye Bioscience, Inc. announced that it has received $49.99101 million in funding

Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding

Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye Bioscience, Inc. Announces Board Appointments

New major risk - Share price stability

Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors

Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

Skye Bioscience, Inc. Appoints Chris Twitty as Chief Scientific Officer

Skye Bioscience, Inc. (OTCPK:SKYE) completed the acquisition of Emerald Health Therapeutics, Inc. (CNSX:EMH) from Emerald Health Sciences Inc. and others.

Skye Bioscience, Inc. Completes Drug Production for Phase 1 Clinical Study

Skye Bioscience, Inc. Updates Phase 1 Timeline

Skye Bioscience, Inc. Announces Resignation of Jim Heppell as A Member of Board of Directors, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee

Skye Bioscience, Inc. (OTCPK:SKYE) entered into a definitive agreement to acquire Emerald Health Therapeutics, Inc. (CNSX:EMH) for CAD 21.7 million.

Skye Bioscience, Inc. Reports Positive Results for SBI-100 in GLP Toxicology Study

Skye Bioscience, Inc. Reports Potential Neuroprotective Benefit of SBI-100 in Preclinical Glaucoma Model

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, Both as Combination and Single Agent, in Preclinical Study

Skye Bioscience, Inc. Announces Board Appointments

Emerald Bioscience Inc., Annual General Meeting, Jan 28, 2021

Emerald Bioscience Inc. Provides an Update on Progress across its Product Pipeline, including adjusted clinical milestones

Emerald Bioscience Inc. Announces Changes in Principal Financial Officer

Emerald Bioscience Inc. Announces Executive Changes

Emerald Bioscience Inc. has completed a Composite Units Offering in the amount of $6.939667 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin